Abstract: Our findings suggest that TRPA1 enhances cisplatin-induced AKI via modulation of ERS and mitochondrial damage.
Introduction
Cisplatin remains a cornerstone of cancer chemotherapy, yet its clinical utility is severely hampered by nephrotoxicity; approximately 20–30% of patients develop acute kidney injury (AKI). While oxidative stress and inflammation are known contributors, the precise molecular "cross-talk" between cellular organelles during cisplatin-induced injury has remained elusive. This study identifies the Transient Receptor Potential Ankyrin-1 (TRPA1) cation channel as a central regulator that links endoplasmic reticulum (ER) stress to mitochondrial failure, driving renal tubular cell death.
Mechanistic Insights: The ERS-Mitochondrial Axis
The researchers discovered that TRPA1 activation triggers a destructive interaction between the ER and mitochondria. Cisplatin increases the contact area at the Mitochondria-Associated ER Membrane (MAM), the physical tether between these organelles. TRPA1 facilitates a massive influx of $Ca^{2+}$, which induces ER stress and upregulates the chaperone protein GRP75. This protein stabilizes the MAM, funneling lethal amounts of calcium into the mitochondria, leading to swelling, membrane potential collapse, and eventual burst.
Methods
The study employed a dual-model approach to dissect these pathways:
- In Vivo: Male C57BL/6 mice were treated with cisplatin to induce AKI. A subset of mice received the TRPA1 inhibitor HC-030031 to evaluate its protective effects.
- In Vitro: Human renal tubular epithelial (HK-2) cells were used to observe molecular dynamics, including calcium flux and mitochondrial fission/fusion protein expression.
Key techniques included Transmission Electron Microscopy (TEM) to visualize MAM structural changes, Western blotting for stress markers (GRP78, CHOP), and JC-1 assays to measure mitochondrial membrane potential.
Experimental Results
Inhibition of TRPA1 provided significant protection against cisplatin-induced damage. In mouse models, the administration of HC-030031 significantly reduced serum creatinine (Scr) and blood urea nitrogen (BUN) levels. Histopathological analysis confirmed that TRPA1 inhibition preserved renal architecture, reducing tubular injury and protein cast formation. Furthermore, TUNEL staining demonstrated a marked decrease in the percentage of apoptotic cells in kidney tissues when TRPA1 was inhibited.
Discussion and Future Directions
The study highlights TRPA1 as a critical "lynchpin" in the progression of AKI. By shifting the mitochondrial balance away from fragmentation (fission) and toward repair (fusion), TRPA1 inhibition effectively breaks the "death spiral" between the ER and mitochondria.
While these results are promising, limitations remain. The transition from mouse models to human clinical trials requires careful evaluation of the safety and specificity of TRPA1 inhibitors. Future research should also investigate the optimal therapeutic window for administering these inhibitors alongside chemotherapy to maximize renal protection without compromising anti-tumor efficacy.
Summary updated